| Autor: |
Dutta, Bikram Singh, Shahnawaz, Mir, Mustafa, Hena, Masoodi, Shariq R., Farooq, Syed Suraiya, Dar, Mohd Yousoof, Dar, Khurshid Ahmad, Shah, Naveed Nazir |
| Předmět: |
|
| Zdroj: |
JK Practitioner; Oct-Dec2021, Vol. 26 Issue 4, p64-70, 7p |
| Abstrakt: |
Background and objectives Kashmir is an intermontane valley located in the inner Himalayan region of North India.The first case of COVID-19 emerged here in mid-March 2020; the current study aimed to describe clinical characteristics of COVID-19 disease in a developing region of Indian subcontinent. Methods In this descriptive study, data of 140 laboratory-confirmed COVID-19 patients (Males 86, 61%) admitted in a single centre from 22nd March to 20th of May 2020 were analysed. Severe illness was defined as a composite endpoint of admission to an intensive care unit (ICU), use of mechanical ventilation, or death. Results Mean age of the study subjects was 37.2 years with no significant gender difference in the age. Only 55 (39.3%) patients were symptomatic; fever, cough, anorexia and sore throat were the most common symptoms reported.69% had a history of contact, 14% had travel history while 16% had no history of contact/travel. 54 (38.5%) patients were from ten family clusters. 45 (32.1%) patients had chronic comorbidities with hypertension as the most common comorbidty. Lymphopenia was seen in 46 (36.2%) patients while 25% of patients (90% with severe illness) showed abnormalities in chest CT. Compared to non-severe patients, the severe patients were older, more symptomatic with comorbidities and had more laboratory/CT abnormalities. The composite endpoint occurred in 10 patients (7.1%) of whom seven patients (5.1%) died. Conclusion COVID-19 in developing regions like ours is a mild disease with the majority being relatively young and asymptomatic. Older age, and hypertension are associated with poor clinical outcome. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
